Senior Scientist, NGS Assay Development (Hyb & Seq)

Organization
NanoString Technologies
Job Location
Seattle, WA 98109
Salary
Competitive
Benefits

Comprehensive

Job Description

Job Summary:

NanoString is seeking an experienced and technology-savvy molecular biologist or biochemist, to join our Research & Development group.  This position will have a leading role in developing sequencing based assays using Hyb & SeqTM, a novel single-molecule hybridization-based next generation sequencing (NGS) technology.  S/he will lead NGS assay development by interacting and coordinating with a highly interdisciplinary group of technologists to create industry-leading assay products.  The successful candidate must be prepared to be a hands-on experimentalist while guiding a team in wet-lab driven research to create innovative solutions to development hurdles.  Candidates must have strong analytical skills, strong oral and written communication skills, and a track record of building NGS panel products.

Essential Duties:

  • Apply advanced and expert scientific and product knowledge to NGS assay development projects
  • Contribute to assay product conceptualization working closely with business analyst and strategic marketing specialists
  • Establish sample preparation, quality and input requirements and assay workflows
  • Conceive, design and carry-out experiments for fast development of prototype panels for feasibility testing
  • Collaborate with analysts and programmers to develop a bioinformatics analysis pipeline
  • Design and implement assay studies to test and refine both newly developed and/or existing genomics analysis tools and pipelines
  • Work interactively with biophysicists, nucleic-acid chemists, fluorescence imaging specialists, and hardware and software engineers for full system development


Other

  • NanoString is an EOE
  • NanoString participates in E-Verify. E-Verify is a web-based system that allows an employer to determine an employee's eligibility to work in the US using information reported on an employee's Form I-9. The E-Verify system confirms eligibility with both the Social Security Administration (SSA) and Department of Homeland Security (DHS). For more information, please go to the USCIS E-Verify website.
Requirements

Requirements:

  • Ph.D. in Life / Physical Sciences
  • 7+ years of combined industry and post-doctoral work experience in NGS, with significant portion dedicated to NGS panel assay development
  • Extensive hands-on, state-of-the-art molecular biology experience
  • Knowledge of nucleic acid characterization techniques, especially hybridization-based assays
  • Experience working with clinically relevant sample types such as FFPE, whole blood and plasma
  • Experience in cancer genomics (knowledge of oncogenic pathways) and/or infectious disease genomics
  • Expert in navigating and extracting information from publicly available databases (NCBI, UCSC, Ensembl, COSMIC, etc.)
  • Familiarity with commonly used algorithms for alignment and variant calling (SNV, InDel, CNV, Fusion, etc.)
  • Experience analyzing and interpreting NGS data from tumor and/or liquid biopsy samples
  • Experience working with NGS bioinformatics teams

 Additional Desirable Qualifications include:

Experience working with microfluidic devices
Experience leading small teams for assay development 

About Our Organization

NanoString Technologies is a publicly held provider of life science tools for translational research and molecular diagnostics. The company's technology enables a wide variety of basic research, translational medicine and in vitro diagnostics applications.

NanoString's products are based on a novel digital molecular barcoding technology invented at the Institute for Systems Biology (ISB) in Seattle under direction of Dr. Leroy Hood. The company was founded in 2003 with an exclusive license to develop and market the technology. In 2008, NanoString launched its first commercial instrument system and began international sales operations with its first multiplexed assays for gene expression analysis. In 2010, the company launched new applications for the system to support microRNA analysis and copy number variation detection, and in 2013 launched Prosigna®, its first in vitro diagnostic product for prognosis of early stage breast cancer.

New study finds bias against female lecturers among student course evaluations, the Economist reports.

A research duo finds that science and technology graduate students who turn away from academic careers do so because of changes in their own interests.

Students whose classmates are interested in science are more likely to think about a career in science, technology, engineering, and mathematics, a new study says.

CNBC reports that the genetic counseling field is expected to grow as personalized medicine becomes more common.